KLK3/PSA Polyclonal Antibody for IHC, WB, ELISA
Cat no : 10679-1-AP
APS, Gamma seminoprotein, hK3, Kallikrein 3, kallikrein related peptidase 3, KLK2A1, KLK3, P 30 antigen, Prostate specific antigen, PSA, Semenogelase, Seminin
|Positive WB detected in||LNCaP cells, Transfected HEK-293 cells|
|Positive IHC detected in||human prostate cancer tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Western Blot (WB)||WB : 1:1000-1:8000|
|Immunohistochemistry (IHC)||IHC : 1:100-1:400|
|Sample-dependent, check data in validation data gallery|
10679-1-AP targets KLK3/PSA in WB, IHC, ELISA applications and shows reactivity with human samples.
|Host / Isotype||Rabbit / IgG|
|Immunogen||KLK3/PSA fusion protein Ag1060|
|Full Name||kallikrein-related peptidase 3|
|Calculated molecular weight||29 kDa|
|Observed molecular weight||30-34 kDa|
|GenBank accession number||BC005307|
|Gene ID (NCBI)||354|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.1% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. kallikrein-related peptidase 3, which is also called PSA (prostate-specific antigen) in the clinical setting, is useful in the diagnosis and monitoring of prostatic carcinoma. KLK3 has 5 isoforms produced by alternative splicing.
J Exp Med
Wnt5a induces and maintains prostate cancer cells dormancy in bone.
J Cell Biochem
Identification of reciprocal microRNA-mRNA pairs associated with metastatic potential disparities in human prostate cancer cells and signaling pathway analysis.
KLF5 Is Crucial for Androgen-AR Signaling to Transactivate Genes and Promote Cell Proliferation in Prostate Cancer Cells.
Mol Cancer Ther
The combination of metformin and valproic acid induces synergistic apoptosis in the presence of p53 and androgen signaling in prostate cancer.